cystic fibrosis

[Journal of Clinical Investigation] To learn whether inflammation alters cystic fibrosis (CF) airway surface liquid pH, researchers treated CF epithelia with TNFα and IL-17, two inflammatory cytokines that are elevated in CF airways.

[CF Foundation (BuisnessWire, Inc.)] CF Foundation announced a new collaboration with venture creator Deep Science Ventures, focused on uncovering and designing new technologies with the potential to overcome challenges to developing genetic therapies for cystic fibrosis.

[Biology of Reproduction] The authors isolated basal cells from the rat epididymis and established 3-dimensional cell cultures from the basal and non-basal cell fractions. Organoids were formed by single adult epididymal basal cells.

[AzurRx BioPharma, Inc. (Globenews Wire, Inc.)] AzurRx BioPharma, Inc., announced positive interim data from the first 18 out of 20 patients in its Phase II trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (PERT), for the treatment of severe exocrine pancreatic insufficiency in patients with cystic fibrosis.

[Pharmacological Reports] Transforming growth factor-beta (TGF-β), by internalization of the epithelial sodium channel (ENaC), suppresses the anti-oxidant system, downregulates the cystic fibrosis transmembrane conductance regulator (CFTR), and activates the plasminogen activator inhibitor 1 (PAI-1) and nuclear factor-kappa-light-chain-enhancer of activated B cells (NF-kB).

[Vertex Pharmaceuticals, Inc.] Vertex Pharmaceuticals, Inc. announced that the European Commission has granted approval of the label extension for KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of cystic fibrosis in all patients ages 12 years and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene.